Geoffrey Ku, MD, summarizes the FIGHT clinical trial as presented at ASCO GI 2021
Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, tells us about bemarituzumab (an anti-FGFR2b antibody) and elaborates on results from the FIGHT study investigating bemarituzumab plus chemotherapy in the first-line treatment of gastric and gastroesophageal (GE) junction cancers as presented at the 2021 Gastrointestinal Cancers Symposium
Geoffrey Ku, MD, considers the mechanism of action and future development of zanidatamab
Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, discusses zanidatamab (a bi-specific anti-HER2 antibody) and the updated data investigating zanidatamab in HER2+ biliary tract cancer and gastroesophageal (GE) junction adenocarcinoma presented at ASCO GI 2021
Geoffrey Ku, MD, regarding the use of trastuzumab deruxtecan in gastric or GE junction cancer
Dr. Ku, GI Medical Oncologist, Memorial Sloan Kettering Cancer Center, offers opinion on the FDA approval of trastuzumab deruxtecan for the treatment of locally-advanced or metastatic HER2+ gastric or gastroesophageal (GE) junction adenocarcinoma
Tanios Bekaii-Saab, MD, FACP, offers opinion on the updated KEYNOTE-177 as presented at ASCO GI 2021
Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinical College of Medicine and Science, Vice-Chair and Section Lead, Mayo Clinic Cancer Center, Division of Medical Oncology, considers outcomes from KEYNOTE-177 investigating the use of pembrolizumab in the first-line treatment of MSI high colorectal cancer (CRC)
Tanios Bekaii-Saab, MD, FACP, summarizes data regarding circulating tumor cells from ASCO GI 2021
Dr. Bekaii-Saab, Professor of Gastrointestinal Cancer, Mayo Clinical College of Medicine and Science, Vice-Chair and Section Lead, Mayo Clinic Cancer Center, Division of Medical Oncology, provides an overview of the data presented at the 2021 Gastrointestinal Cancers Symposium regarding circulating tumor cells and the use of this test as a prognostic tool for patients with a high risk of recurrence
Richard S. Finn, MD, regarding the updated IMbrave150 data from ASCO GI 2021
Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, Jonsson Comprehensive Cancer Center at UCLA, discusses updates from the Phase 3 IMbrave150 trial investigating combination atezolizumab and bevacizumab compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC) as presented at the 2021 Gastrointestinal Cancers Symposium
Richard S. Finn, MD, tells us about the safety profile of atezolizumab & bevacizumab from IMbrave150
Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, Jonsson Comprehensive Cancer Center at UCLA, tells us about the safety profile of atezolizumab and bevacizumab in the Phase 3 IMbrave150 trial investigating combination atezolizumab and bevacizumab compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC)
Richard S. Finn, MD, considers whether updated results from IMbrave150 are practice-changing
Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, Jonsson Comprehensive Cancer Center at UCLA, offers opinion on whether the final overall survival findings from the Phase 3 IMbrave150 is practice-changing
Richard S. Finn, MD, offers opinion on the role of frontline atezolizumab + bevacizumab in HCC
Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, Jonsson Comprehensive Cancer Center at UCLA, offers opinion on the role of combination atezolizumab + bevacizumab in the frontline setting for patients with refractory hepatocellular carcinoma (HCC)
Richard S. Finn, MD, elaborates on promising developments in the second-line treatment of HCC
Dr. Finn, Professor, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, Director, Signal Transduction and Therapeutic Program, Jonsson Comprehensive Cancer Center at UCLA, elaborates on promising developments in the second-line treatment of hepatocellular carcinoma (HCC) and provides an overview of the CheckMate 040 trial and KEYNOTE-240 from the 2021 Gastrointestinal Cancers Symposium
Namrata Vijayvergia, MD, discusses updates from the IMbrave150 trial as presented at ASCO GI 2021
Dr. Vijayvergia, Assistant Professor of Hematology and Oncology, Assistant Chief of GI Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, discusses updates from the Phase 3 IMbrave150 trial investigating combination atezolizumab and bevacizumab compared with sorafenib in previously untreated patients with advanced hepatocellular carcinoma (HCC) as presented at the 2021 Gastrointestinal Cancers Symposium
Namrata Vijayvergia, MD, considers updated data from the CheckMate 040 trial in advanced HCC
Dr. Vijayvergia, Assistant Professor of Hematology and Oncology, Assistant Chief of GI Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, considers the updated data from the CheckMate 040 trial investigating nivolumab + ipilimumab + cabozantinib combination therapy in patients with advanced hepatocellular carcinoma (HCC) as presented at ASCO GI 2021
Namrata Vijayvergia, MD, offers opinion on the use of FGFR inhibitors in the treatment of CCA
Dr. Vijayvergia, Assistant Professor of Hematology and Oncology, Assistant Chief of GI Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, offers opinion on recent advances in the use of FGFR inhibitors in the treatment of cholangiocarcinoma (CCA)
Andrew X. Zhu, MD, PhD, discusses the final results of the ClarIDHy trial from ASCO GI 2021
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, discusses the final results of the Phase 3 ClarIDHy trial investigating ivosidenib in patients with previously treated IDH1-mutant cholangiocarcinoma as presented at the 2021 Gastrointestinal Cancers Symposium
Andrew X. Zhu, MD, PhD, speculates on the potential impact of the ClarIDHy trial
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, considers the potential impact of the ClarIDHy trial
Andrew X. Zhu, MD, PhD, elaborates on the role of genetic testing in cholangiocarcinoma
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, elaborates on the role of genetic testing in patients with cholangiocarcinoma (CCA)
Andrew X. Zhu, MD, PhD, on ivosidenib as a 1st line therapy for patients with CCA & an IDH1 mutation
Dr. Zhu, Director Emeritus, Liver Cancer Research, Mass General Hospital Cancer Center, Director, Jiahui International Cancer Center, Professor of Medicine, Harvard Medical School, offers opinion on ivosidenib as first-line therapy for patients with cholangiocarcinoma (CCA) and an IDH1 mutation
Thomas J. George, MD, regarding the NRG-GI002 trial as presented at ASCO GI 2021
Dr. George, Director, GI Oncology Program, University of Florida, discusses primary results from the NRG-GI002 trial as presented at the 2021 ASCO Gastrointestinal Cancers Symposium
Zev Wainberg, MD, elaborates on outcomes from the FIGHT trial as presented at ASCO GI 2021
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, tells us about the results of the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Thomas J. George, MD, elaborates on the design of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, elaborates on the design of the NRG-GI002 clinical trial
Zev Wainberg, MD, discusses the safety profile of bemarituzumab
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, discusses the safety profile of bemarituzumab from the Phase 2 FIGHT trial, investigating first-in-class targeted therapy bemarituzumab in advanced gastric or gastroesophageal junction (GEJ) cancer
Thomas J. George, MD, considers results from the experimental arms of the NRG-GI002 clinical trial
Dr. George, Director, GI Oncology Program, University of Florida, considers results from the experimental arms of the NRG-GI002 clinical trial
Zev Wainberg, MD, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Dr. Wainberg, Co-Director, UCLA GI Oncology Program, Medical Director, UCLA Colorectal Cancer Center, Assistant Professor of Medicine, Division of Hematology Oncology, David Geffen School of Medicine, speculates on the role of bemarituzumab in other FGFR2b-positive tumor types
Thomas J. George, MD, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial
Dr. George, Director, GI Oncology Program, University of Florida, discusses the side effect profile of pembrolizumab in the NRG-GI002 trial as presented at the 2021 Gastrointestinal Cancers Symposium
Thomas J. George, MD, on the evolving treatment landscape of locally advanced rectal cancer
Dr. George, Director, GI Oncology Program, University of Florida, speculates on the evolving treatment landscape of locally advanced rectal cancer and whether potential improvements in outcomes are on the horizon for this disease
Rachna Shroff, MD, tells us about the NuTide:121 trial as presented at GI 2021
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, tells us about the NuTide:121 trial as presented at the 2021 Gastrointestinal Cancers Symposium
Rachna Shroff, MD, elaborates on newly approved targeted therapies in esophagogastric cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, elaborates on newly approved targeted therapies in esophagogastric cancer
Rachna Shroff, MD, shares perspective on newly approved targeted therapies in hepatobiliary cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, shares perspective on some of the newly approved targeted therapies in hepatobiliary cancer
Rachna Shroff, MD, on the most promising pathways for targeted therapies in GI cancers
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, discusses the most promising pathways for targeted therapies in hepatobiliary and esophagogastric cancers
Rachna Shroff, MD, considers the progress of targeted therapies in GI cancer
Dr. Shroff, Medical Director, Clinical Trials Office, Chief, Section of GI Medical Oncology, University of Arizona Cancer Center, considers how the progress of targeted therapies in GI cancer compares with progress seen in other tumor types
Geoffrey Y. Ku, MD, offers opinion on the practice-changing potential of the CheckMate-649 study
Dr. Ku, Medical Oncologist, Memorial Sloan Kettering Cancer Center, offers opinion on the practice-changing potential of the CheckMate-649 study investigating nivolumab plus chemotherapy in gastric/GE junction cancer presented at the 2020 ESMO Virtual Congress
Jaffer Ajani, MD, considers results from the CheckMate 649 study presented at ESMO 2020
Dr. Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, considers the CheckMate 649 study investigating nivolumab and chemotherapy in gastric/GE junction cancer and whether particular subgroups of patients appear more likely to respond to this therapy
Jaffer Ajani, MD, provides opinion on the role of I-O in treatment of esophageal & gastric cancers
Dr. Ajani, Professor, Department of Gastrointestinal (GI) Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, provides opinion on whether immuno-oncology (I-O) is making meaningful clinical progress as the backbone of treatment for esophageal and gastric cancers
Zarnie Lwin, MBBS, FRACP, shares the design & outcomes of the LEAP-005 Phase II study from ESMO 2020
Dr. Lwin, Associate Professor, University of Queensland, Consultant Medical Oncologist, Cancer Care Services, Royal Brisbane and Women’s Hospital, shares the design and outcomes of the LEAP-005 Phase II study investigating the combination of pembrolizumab and lenvatinib in gastrointestinal (GI) cancer presented at the 2020 ESMO Virtual Congress
Howard Hochster, MD, explains the role of ramucirumab in the treatment of GE junction cancers
Dr. Hochster, Distinguished Professor of Medicine, Rutgers Cancer Institute, explains the role of Cyramza (ramucirumab) in the treatment of GE junction cancers
Alan Venook, MD, provides thoughts on the clinical progress of trastuzumab-deruxtecan in GI cancers
Dr. Venook, Shorenstein Associate Director for Program Development, Helen Diller Family Comprehensive Cancer Center, provides thoughts on the clinical progress of Enhertu (trastuzumab-deruxtecan) in GI cancers such as gastric and colorectal cancer
Follow @OBRTweets